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SUMMARY
Behavioral and biochemical effects of xylazine were studied both in rats and mice. The results 
showed that xylazine: a) decreased the general activity of rats and mice observed in an open 
field; b) was unable to produce catatonia and suppressed haloperidol-induced catatonia in mice; 
c) increased apomorphine-induced stereotyped behavior in rats; and d) increased brain 
noradrenaline without effect on brain dopamine levels. These results were discussed in the light 
of a possible interference of xylazine with brain noradrenergic system and, thus, with the 
dynamic interaction between noradrenergic-dopaminergic neurons within the Central Nervous 
System.
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INTRODUCTION
Xylazine(Rompun, Bay 1470, 2-(2,6dimethyl-phcnylamino)-
5-6-dihydro-4H-l, 3 thiazine) is a drug widely used in 
veterinary not only for its sedative and nonnarcotic-analgesic 
restraining properties, but also for its muscle relaxant effects 
in a large number of animal species (SPINOSA; SPINOSA2*, 
1991). It has been suggested that xylazine is an alpha , 
adrenergic agonist (BERTHFLSFN ; PETTINGER4, 1977- 
K O B IN G ER ; PIC H L E R  l4, 1983; T R A N Q U IL L I; 
THIJRMON’1, 1984) similar to clonidinc.
Several different receptors and synaptic mechanisms may be 
influenced by the direct and indirect actions of xylazine and/ 
or cion idi ne namely, beta-adrenergic (M AGGI ct al.20, 1980), 
cholinergic (KRONEBERG et al.15, 1967 ; SCHIMITT et 
al.22, 1974; TIM M ERM ANS; van ZW IETEN '0, 1982), 
serotonergic (TIMMERMANS; van ZW IETEN'0, 1982), 
dopam in erg ic  (A N T E L M A N ; C A G G IU L A 1, 1977; 
GOLDBERG; ROBERTSON’, 1983) and opioid rcccptors 
(FARSANG et al.h, 1980).
Although xylazine has been used clinically for over 20 years, 
its effects on Central Nervous System are not totally known. 
The present study was undertaken to characterize some 
behavioral and biochemical effects o f xylazine and its
involvement with central catecholaminergic system. 
MATERIAL AND METHOD
Animals
Male Wistar rats, 250-330 g, and male Swiss Webster mice,
25-35 g, from our colony, were used. Seven days before the 
beginning of the experiments, the rats were randomly housed 
(groups of three or individually) in wire mesh cages (16 x 30 
x 19 cm) and mice (groups of twenty) in plastic cages (17 x 
27 x 14 cm), at 21-23°C on a 12-hr light-dark cycle (lights on 
7:30 a.m.) with free access to food and water, except at the 
observation periods. Each animal was used once.
Drugs
Xylazine (Rompun, Bayer of Brazil) and haloperidol (Haldol, 
Janssen Pharmaceutica) were obtained in commercially 
available ampoules. Apomorphine hydrochloride (Sandoz) 
dissolved in distilled water was also used. Drugs were 
administered i.p., except apomorphine was administered s.c., 
in volume no greater than 2.0 ml/kg of body weight. All doses 
refer to the salt.
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EXPERIMENT 1 - OPKN FIELD STUDIES
Two open fields were constructed based on that described by 
BROADHURST' (I960 ); one for rats (97 cm diameter) and 
other for mice (40 cm diameter). I land-operated counters and 
stop-watches were employed in both aparathus to score 
ambulation frequency (number of floor units entered), rearing 
frequency (number of times the animal stood on hind legs) and 
immobility duration (total seconds of lack of movement).
Both mice and rats were divided at random into three expe­
rimental and one control groups with 10 animals each. 
Experimental animals were treated with xyla/.ine( I. 10 or 30 
mg/kg); control animals received the same volume of NaCl
0.9%. Fifteen minutes after treatments, the animals were 
individually placed in the center of the open field arena for 
behavioral observations that lasted 3 minutes; this procedure 
was repealed 3 0 .6 0 .120 and 180 minutes after drug or control 
solution injections. The open field was cleaned with water- 
alcohol (5%;) solution before placing subjects in order to 
eliminate possible biasing effects of odor clues left by previous 
subjects. To minimize possible circadian influences on animal's 
open field behavior, experimental and control animals were 
intermixed; observations were performed between 1.30 and 
5.30 p.m. An analysis of variance followed by Duncan’s test 
(SPIEGEIP , 1972) was applied to analyse the open field data, 
since the Bartlct's test (JOHNSON; LEO N E", 1964) showed 
the presence of homocedasticity among open field data. The 
probability level o f p < 0.05 was considered the critical 
criterion for all statistical evaluations.
EXPERIMENT 2 - CATATONIA STUDIES
Eighteen mice were divided at random into 3 equal groups. 
Mice of one group received S mg/kg of haloperidol and 30 
minutes later 10 ml/kg of NaCl 0.9%; mice of the 2nd group 
received 10 ml/kg of NaCl 0.9% and 30 minutes later, 30 mg/ 
kg of xyla/inc, finally animals of the 3ri1 group received 8 mg/ 
kg of haloperidol and 30 minutes later, 30 mg/kg of xylazine. 
Catalonia was measured 15,45, 75 and 105 minutes after the 
last injection through animal’s immobility duration (total sec 
of lack of movement). For this, mice were individually tested 
for their permanence on the upright position, with their 
Ibrepaws flatted against one horizontal bar placed 4.5 cm 
above the bench. Each mouse was tested three times for 
catatonia at each time interval and the sum of 3 immobilities 
in each time was used to perform the statistical analysis. Thus, 
an analysis of variance followed by Duncan’s test (SPIEGEL27, 
1972) was used to investigate possible differences among the 
catatonia durations. The level o f significance to show 
differences was also p < 0.05.
EXPERIMENT 3 - STEREOTYPY STUDIES
Rats were divided at random into one experimental (23 
animals) and one control (22 animals) groups. Experimental 
animals received 10 mg/kg -yla/ine and . 15 minutes later, a 
s.c. injection of apomorphiue. Animals of the control group 
received the same volume of NaCl 0.9%, 15 minutes before 
apomorphine administration.
Animals were observed individually for stereotyped behavior 
in wire-mcsh cages. Stereotypy was quantified every 10 
minutes, for 3'" after apomorphine treatment using a scoring 
system proposed elsewhere (SET1 ,ER et a l.’\  1976). Briefly, 
scores varying from 0 (asleep or stationary) to 6 (continual 
licking and/or gnawing in cage grids) were assigned to each 
animal, by an observer who was unaware of the drug treatment. 
This rating is not subjective; an excellent inter-observer 
agreement has been noted elsewere (SO U /A : PALERMO 
NETO'5, 1982) between scores from two different observers 
(Pearson’s correlation, R = 0.98). Four doses of apomorphine 
(0.1 . 1.0. 3.0 and 10.0 mg/kg) were used. The median of the 
total sum of the stereotypy scores obtained 180 minutes after 
each apomorphine dose was used to construct the dose- 
response curve. Data of the experimental groups were compared 
to those of the control group using the Mann-Whitney U test 
(SIEGEL24, 1975). Differences were considered significant 
when p < 0.05.
EXPERIMENT 4 - BIOCHEMICAL STUDIES
Mice were randomly divided into 2 experimental ( 19 animals) 
and 2 control ( 17 animals) groups. The experiment was done 
in two replications: one for dopam ine and other for 
noradrenaline determinations. In each replication, experi­
mental animals received 30 mg/kg of xylazine 15 minutes 
before sacrifice and control animals, at the same time, an 
identical volum e o f NaCl 0.9%'. Im m ediately  after 
decapitation, the mice brains were removed, washed in cold 
NaCl 0.9% solution, being dryed and weighed for biochemical 
evaluation. Dopamine was isolated and determined through 
the method of ATACK ' (1973). Noradrenaline isolation was 
performed according to ATACK and M AGN USSON3 (1978). 
being quantified by the method of KE11R et al.” (1976). 
Student’s t lest (SPIEGEL27, 1972) was used to analyse the 
biochemical data. Results were considered significant when 
p < 0.05.
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RESULTS
OPEN FIELD STUDIES
Results of the open field studies are outlined in Tab. 1 and 2 
for rats and mice respectively. As it can be seen, xylazine 
treatment decreased, in both species, ambulation and rearing 
frequencies and increased immobility duration in a dose- 
dependent way (p < 0.05). These effects had longer duration 
for mice; indeed, both ambulation and rearing frequencies 
were still decreased in mice 60 minutes after I mg/kg xylazine 
administration. Rats that received 1 mg/kg were not differ 
from controls 30 minutes after treatment.
CATATONIA STUDIES
Tab. 3 shows the effects o f xylazine on mice’s catatonia. As 
expected, haloperidol treatment was able to induce catatonia; 
however, this behavior was not produced by xylazine 
administration per sc*. It was also found that xylazine 
treatment completely suppressed haloperidol effects in mice.
STEREOTYPY STUDIES
Fig. I shows the complete dose-response curves constructed 
to xylazine effects on apomorphine-induced stereotyped 
behavior in rats. Thus, it was not only feasible to construct 
dose-response curves to apomorphine using the proposed 
stereotypy scores, but also to study quantitatively the xylazine 
effects, since this drug was able to cause a significant leftward 
displacement of the control dose-response curve. Indeed 
stereotypy score were higher (p < 0.05) for all apomorphine 
doses employed, in rats treated with xylazine. The higher 
score observed in xylazine-treatment rats was a consequence 
of increased duration and intensity of this behavior.
BIOCHEMICAL STUDIES
Tab. 4 shows the effects of xylazine treatment on dopamine 
and noradrenaline whole brain levels in mice. Thus, xylazine 
administration had no effects on dopamine brain levels, but 
significantly increased those of noradrenaline (p < 0.05).
DISCUSSION
G enera l a c tiv ity  has been re la ted  to the cen tra l 
catecholaminergic system, whereas catatonia and stereotypy 
arc related to central dopaminergic systems (MASON 21, 
1984). These behaviors were used, in present work, to study 
xylazine effects. Thus, xylazine decreased then open field 
behavior o f rats and mice in a dose-dependent way. This result 
is in agreement with previous research on the sedative effects
TABLE 1
Effects of xylazine administration on open field behavior of rats. 
Data arc means ± SD: * p < 0.05. Anova and Duncan’s test. Sào 
Paulo. 1987.
observation xylazine dose (mg/kg)parameter (min)
■N.K 1
0.9% 1 10 30
15 34± 16 22±4* 3±3* 1±3*
ambulation 30 17± 10 l()±6 2±5* 2±6*
frequency 60 22±l 1 15± 11 l()±7* 4+6*
(number) 120 I4±9 24±8 23± 12 • 5±4
180 25±6 16± 1 1 21 + 10 5±5*
15 13±5 9±2* l + l* 0±0*
rearing 30 5±5 5±4 l±3 0±1*
frequency 60 9±6 5±5 3+3* 1±1*
(number) 120 5 ±3 11 ±3* 8±5 1±2
180 11±3 6+6 9±5 2+2*
15 6±9 36+33* 168±15 178±4*
immobility 30 19± 14 54+14* I64±38* I64±27*
duration 60 12+9 39±29 73±28* 160+24*
(sec) 120 34±2() 14+10 20± 13 90+46*
180 18±8 40± 19 27+21 82±47*
TABLE 2
Effects of xylazine administration on open field behavior of mice.
Data are means ± SD; * p < 0.05, Anova and Duncan’s test. São
Paulo, 1987.
parameter observation NaCI
xylazine dose (mg/kg)
(min) 0,9% 1 10 30
15 75+21 43±16* 24+16* 22+21 *
ambulation 30 47+21 32+15* 7+4* 18±14*
frequency 60 46+22 25±15* 14+13* 12±I3*
(number) 120 41 ±23 27± 13 72±I5* 12±I0*
180 3()±22 29± 12 55±34 37±21
15 I7±8 7±5* 2±2* 2±3*
rearing 30 13± 10 6±8* ()±0* l±2*
frequency 60 I4±8 6+7* <)±0* l±l*
(number) 120 1()±8 6±6 9±8 l±l*
180 5 ±6 5 ±4 10±7 5+6
15 l±2 38+31 * 107±56 97±42*
immobility 30 12± 17 50±46* 138±21 * 113±44*
duration 60 16±49 49±51 129±32* 128±44*
(aec) 120 13± 18 35±33 14± 16 118±47*
180 36+47 ■ 28±34 24±46 50±60
of xylazine (HSU 1981; HATCH et al.8, 1982) and some 
q u a lita tiv e  o b se rv a tio n s  perfo rm ed  w ith d iffe ren t
metodologics in several animal species (HOFFMAN9, 1974; 
LEWIS ct al.18, 1983; KALPRAVIDH et a l.'2, 1984).
223
SPINOSA, H.S.; GÓKNIAK. S I..; PALERMO NETO. J.: BERNARDI, M.M. Behavioral anil hiochcinical cffccls o f xyla/.ine: possible intcraclions between
central noradrenergic-dopaminergic systems. Braz. J .  vet. Res. an im . Sci., São Paulo. v.30. p.221-6. 1993. Suplemento.
TABLE 3
Effects of xylazine administration on halopcridol-iniluced catatonia 
in mice. Data are means ± SD (in min). São Paulo, 1987.
haloperidol xylazine observation moments (mitt)
(mg/kg) (mg/kg)
15 45 75 105
X I5.7±4.9 15.1 ±5.4 15.1 ±6.4 12.3±6.1
30 0  0 0 0
X 30 0 0 0 0
TABLE4
Effects of xyla/inc treatment on dopamine and noradrenaline 
brain levels of mice. Data arc means ±SD ; number in brackets 
represent number of animals used; * p < 0.05 . Student's t test. 
São Paulo, 1977.
group
brain level s (ug/g)
dopamine noradrenaline
control 0.96+0.26
(9)
1,77±0.55 
(8 )
experimental 0.91 ±0.20 2.35±0.49
/Ol
APO M O RPH IJN B (m g/kg) 
FIGURE 1
Effects of xyla/.ine administration (10 mg/kg - open circles) on 
apomorphine - induced stereotyped behavior in rats. Data show the 
median of the sum of the stereotypy scores observed after each 
apomorphine dose; number of animals tested at each apomorphine 
dose is showed in brackets. An asterisk on top of circles means a 
statistically significance from control data (full circles) p < 0.05 
(Mann-Whitney U Test).
The participation of noradrenaline on xyla/inc effccts on 
open field behavior seems to be plausible. In fact, olhcr alpha, 
adrenoceptor agonist, clonidine, is able not only to decrease 
rat’s general activity but also to induce sedation (LA VERTY; 
TAILOR17, 1969 ; TILSON et al.M, 1977). In addition, alpha, 
adrenoceptor agonist decreases noradrenaline release from 
no rad ren erg ic  neu rons (M cA F F E  et a l .19, 1981; 
TRANQUILLI; TH U R M O N '1, 1984), w ithout altering 
dopamine levels; sim ilar effects on catecholam inergic 
neurotransmitter levels were observed in the present work.The 
higher dose of xyla/inc did not induce catatonia per se (as 
haloperidol, a dopaminergic blocker); xyla/ine, contrary, 
induced flaccidity and no rigidity. A similar effect was 
observed with clonidine (K U LK A R N IK\  1981). The 
anticatatonic effect of xylazine may result from muscle 
relaxation by action on alpha, adrenergic receptors or be due 
to some other mechanism not yet understood. On the other 
hand, xyla/.ine increased apomorphine-induccd stereotypy, 
suggesting that is possible to exist a balance between central 
noradrenergic-dopaminergic systems on central xylazine
effects. In fact, phenoxybenzamine and phentolamine (alpha- 
adrenoceptor antagonist) also displaced to the left the control 
apomorphine dose-response curve (SOUZA; PALERMO 
NETO26, 1982) like observed with xylazine.
The results presently reported reinforce the suggestion that 
xylazine acts on a lp h a , adrenergic receptors and alters the 
norm al balance betw een  cen tra l norad renerg ic  and 
dopaminergic systems.
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RKSUMO
Alguns efeitos coinportamentais e bioquímicos da xila/.ina Ibram estudados em ratos e camundongos. Os 
resultados mostraram que a xilazina: a) diminuiu a atividade geral de ratos e camundongos observados em 
eainpo-aberto; b) foi incapaz de produzir catatonia e suprimiu este comportamento induzido pelo 
haloperidol cm camundongos; c) potencializou o comportamento estereotipado induzido pela apomorfina 
etn ratos; d) aumentou os níveis cerebrais de noradrenalina. porem não alterou aqueles dc dopamina. Estes 
resultados foram discutidos considerando-se ação da xilazina em sislemas noradrenérgicos centrais c da 
interação entre sistemas noradrenérgicos e dopaminérgicos centrais.
UMTKRMOS: Xilazina: Comportamento animal; Estereotipagem: Catatonia.
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